Connexin 43 is an independent predictor of patient outcome in breast cancer patients. (2019)
Attributed to:
Improving the functional affinity of human anti-glycan monoclonal antibodies (mabs) for cancer therapy
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1007/s10549-018-5063-9
PubMed Identifier: 30474779
Publication URI: http://europepmc.org/abstract/MED/30474779
Type: Journal Article/Review
Volume: 174
Parent Publication: Breast cancer research and treatment
Issue: 1
ISSN: 0167-6806